This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts Have Conflicting Sentiments on These Healthcare Companies: Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX)

Tipranks - Tipranks - Sat May 16, 7:56AM CDT

Companies in the Healthcare sector have received a lot of coverage today as analysts weigh in on Zoetis (ZTS), Sarepta Therapeutics (SRPT) and GoodRx Holdings (GDRX).

Claim 55% Off TipRanks

Zoetis (ZTS)

In a report released today, Erin Wright from Morgan Stanley maintained a Buy rating on Zoetis, with a price target of $115.00. The company’s shares closed last Thursday at $75.48.

According to TipRanks.com, Wright is a 5-star analyst with an average return of 14.7% and a 62.5% success rate. Wright covers the Healthcare sector, focusing on stocks such as BrightSpring Health Services, Inc., Elanco Animal Health, and Option Care Health. ;'>

The word on The Street in general, suggests a Moderate Buy analyst consensus rating for Zoetis with a $132.58 average price target, which is a 78.1% upside from current levels. In a report issued on May 6, TipRanks – xAI also upgraded the stock to Buy with a $127.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

Sarepta Therapeutics (SRPT)

Evercore ISI analyst Gavin Clark-Gartner maintained a Hold rating on Sarepta Therapeutics today and set a price target of $19.00. The company’s shares closed last Thursday at $18.68.

According to TipRanks.com, Clark-Gartner is a 5-star analyst with an average return of 28.1% and a 60.6% success rate. Clark-Gartner covers the Healthcare sector, focusing on stocks such as Ultragenyx Pharmaceutical, Crinetics Pharmaceuticals, and Definium Therapeutics. ;'>

Currently, the analyst consensus on Sarepta Therapeutics is a Hold with an average price target of $21.64, implying a 12.0% upside from current levels. In a report issued on May 5, TipRanks – xAI also upgraded the stock to Hold with a $22.50 price target.

GoodRx Holdings (GDRX)

In a report released today, Jailendra Singh from Truist Financial maintained a Hold rating on GoodRx Holdings. The company’s shares closed last Thursday at $2.49.

According to TipRanks.com, Singh has currently 0 stars on a ranking scale of 0-5 stars, with an average return of -12.4% and a 35.7% success rate. Singh covers the Healthcare sector, focusing on stocks such as Hinge Health, Inc. Class A, Fortrea Holdings Inc., and Revolution Medicines. ;'>

GoodRx Holdings has an analyst consensus of Hold, with a price target consensus of $3.09, implying a 18.4% upside from current levels. In a report issued on May 3, TipRanks – DeepSeek also downgraded the stock to Hold with a $3.00 price target.

Read More on ZTS:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).